Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.

Autor: Dasari A; MD Anderson Cancer Center, University of Texas, Houston, Texas, USA ADasari@mdanderson.org., Bergsland EK; UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA., Benson AB; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Cai B; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Huynh L; Analysis Group, Inc., Boston, Massachusetts, USA., Totev T; Analysis Group, Inc., Boston, Massachusetts, USA., Shea J; Analysis Group, Inc., Boston, Massachusetts, USA., Duh MS; Analysis Group, Inc., Boston, Massachusetts, USA., Neary MP; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Dagohoy CG; MD Anderson Cancer Center, University of Texas, Houston, Texas, USA., Shih BE; UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA., Maurer VE; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Chan J; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kulke MH; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Section of Hematology/Oncology, Cancer Center at Boston Medical Center, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: The oncologist [Oncologist] 2019 Aug; Vol. 24 (8), pp. 1066-1075. Date of Electronic Publication: 2019 Jan 04.
DOI: 10.1634/theoncologist.2018-0520
Abstrakt: Background: Using data from four tertiary referral centers in the U.S., we assessed real-world treatment patterns and clinical outcomes of patients with advanced lung neuroendocrine tumors (NETs).
Subjects, Materials, and Methods: We performed a retrospective chart review of adult patients with locally advanced/metastatic (typical/atypical) lung NETs treated between July 2011 and December 2014. Index date was histologically confirmed typical/atypical carcinoid tumor diagnosis date. Data included baseline characteristics, treatment patterns, progression, death, and lung NET-related health care resource use from index date through last contact/death. Time to treatment discontinuation and first progression, time from first to second progression, and overall survival (OS) were estimated using Kaplan-Meier analysis.
Results: We identified 83 patients; 19 (23%) had functional NET. First-line treatments included somatostatin analogs (SSAs) alone (56%) or in combination with other therapies (6%), cytotoxic chemotherapy (20%), external beam radiation therapy (EBRT) (9%), liver-directed therapy (LDT) (4%), and everolimus/other (5%). Sixty patients had second-line therapy including SSA alone (18%) or in combination (40%), cytotoxic chemotherapy (17%), everolimus (12%), LDT (7%), EBRT (3%), and other treatments (3%). Median time (months) to first-line discontinuation were as follows: SSAs, 43.3; cytotoxic chemotherapy, 3.6. Overall median time (months) to investigator-assessed progression following treatment initiation was 12.4. Median OS (months) following treatment initiation was 66.4 for all patients and 81.5 for patients receiving SSAs.
Conclusion: SSAs, alone and in combination, are common treatments for advanced lung NETs. Patients have additional treatment options and relatively long survival compared with patients with other advanced cancers. Treatment pattern assessment following approval of newer treatments is needed.
Implications for Practice: Somatostatin analogs (SSAs), cytotoxic chemotherapy, EBRT, liver-directed therapy, and targeted therapies are common treatments for locally advanced/metastatic (typical/atypical) lung neuroendocrine tumors (NETs). SSAs alone or in combination with other treatment modalities were the most common first- and second-line therapy, followed by cytotoxic chemotherapy. Patients continued treatment with SSAs long-term with median treatment duration of 43 months. Median overall survival was 66 months following initiation of first-line therapy for all patients. Treatment pattern assessment beyond the time period of this study is needed given recent U.S. Food and Drug Administration approvals for additional treatments for lung NETs that will likely be incorporated in the treatment landscape.
Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article.
(© AlphaMed Press 2019.)
Databáze: MEDLINE
Externí odkaz: